A series of cardiometabolic-related news items have been observed from Lilly, Insulet, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.
In this final installment of the post-ADA promotional series, FENIX is evaluating pumps and AID systems from Insulet, Tandem, Medtronic, and Beta Bionics. In case you missed it, FENIX also conducted analyses of GLP-1RA (previous FENIX insight) and CGM (previous FENIX insight) promotional material from ADA 2024.
A series of cardiometabolic-related news items have been observed from Lilly, Medtronic, Tandem, and EMEA. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Lilly, Tandem, Lexicon, Novartis, and Galectin. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Insulet, Senseonics, Arrowhead, Biocon, and Akero Therapeutics. Below, FENIX provides highlights and insights into the respective news items.
Three cardiometabolic-related news items have been observed: Abbott announced a partnership with Medtronic for the development of a new CGM that is exclusively compatible with Medtronic’s AID and smart insulin pens (press release); Medtronic announced the FDA approval of its Simplera CGM (press release); Madrigal (press release; slides) and MannKind (press release; slides) hosted their respective Q2 ’24 earnings. Below, FENIX provides highlights and insights for the respective news items, along with an analysis of the Abbott/Medtronic partnership.
Dexcom hosted its Q2 ’24 earnings call (press release; slides) and provided updates across its business, including the impending launch of its first OTC CGM (Stelo). Dexcom lowered its full-year guidance which has led to a ~38% drop in the company’s stock price. Below, FENIX provides highlights and insights from the call.
A series of cardiometabolic-related news items have been observed from Novo Nordisk, Viking Therapeutics, AstraZeneca, Roche, and Sanofi. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Roche, Lilly, Pfizer, and the FTC. Below, FENIX provides highlights and insights for the respective news items.
On the third day of ADA 2024, four cardiometabolic-related news items have been observed from Senseonics, Altimmune, Fractyl Health, and Gan & Lee. Below, FENIX provides context and analysis for the announcements.